Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Logothetis

Showing results (191-200 of 430) with videos related to

Pageof 43
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1983
Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancerC J Logothetis, M L Samuels, A C von Eschenbach, et al.
Journal of the National Cancer Institute|January 19, 2019
Radium 223-Mediated Zonal Cytotoxicity of Prostate Cancer in BoneEleonora Dondossola, Stefano Casarin, Claudia Paindelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2008
Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancerRandall E Millikan, Sijin Wen, Lance C Pagliaro, et al.
The Journal of Urology|December 1, 1985
Primary chemotherapy followed by a selective retroperitoneal lymphadenectomy in the management of clinical stage II testicular carcinoma: a preliminary reportC J Logothetis, M L Samuels, D E Selig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2004
Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumorsKarim Fizazi, Stéphane Culine, Andrew Kramar, et al.
Endocrine-Related Cancer|May 6, 2020
Fibroblast growth factors signaling in bone metastasisEstefania Labanca, Elba S Vazquez, Paul G Corn, et al.
Journal of the National Cancer Institute|April 18, 1990
Escalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factorC J Logothetis, F H Dexeus, A Sella, et al.
The Journal of Urology|September 1, 1985
Cyclophosphamide, doxorubicin and cisplatin chemotherapy for patients with locally advanced urothelial tumors with or without nodal metastasesC J Logothetis, M L Samuels, S Ogden, et al.
Journal of the National Cancer Institute|August 19, 1992
Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancerC J Logothetis, H J Xu, J Y Ro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1990
A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumorsC J Logothetis, F H Dexeus, L Finn, et al.
Pageof 43

Showing results (191-200 of 430) with videos related to

Sort By:
Pageof 43
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1983
Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancerC J Logothetis, M L Samuels, A C von Eschenbach, et al.
Journal of the National Cancer Institute|January 19, 2019
Radium 223-Mediated Zonal Cytotoxicity of Prostate Cancer in BoneEleonora Dondossola, Stefano Casarin, Claudia Paindelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2008
Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancerRandall E Millikan, Sijin Wen, Lance C Pagliaro, et al.
The Journal of Urology|December 1, 1985
Primary chemotherapy followed by a selective retroperitoneal lymphadenectomy in the management of clinical stage II testicular carcinoma: a preliminary reportC J Logothetis, M L Samuels, D E Selig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2004
Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumorsKarim Fizazi, Stéphane Culine, Andrew Kramar, et al.
Endocrine-Related Cancer|May 6, 2020
Fibroblast growth factors signaling in bone metastasisEstefania Labanca, Elba S Vazquez, Paul G Corn, et al.
Journal of the National Cancer Institute|April 18, 1990
Escalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factorC J Logothetis, F H Dexeus, A Sella, et al.
The Journal of Urology|September 1, 1985
Cyclophosphamide, doxorubicin and cisplatin chemotherapy for patients with locally advanced urothelial tumors with or without nodal metastasesC J Logothetis, M L Samuels, S Ogden, et al.
Journal of the National Cancer Institute|August 19, 1992
Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancerC J Logothetis, H J Xu, J Y Ro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1990
A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumorsC J Logothetis, F H Dexeus, L Finn, et al.
Pageof 43